Zymeworks Inc. — Director's Dealing 2022

Nov 15, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Zymeworks Inc. (ZYME)
CIK: 0001937653
Period of Report: 2022-11-10

Reporting Person: Josephson Neil (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-11-10	Common Stock	M	5885	$0.00	Acquired	16924	Direct
2022-11-10	Common Stock	S	2475	$8.099	Disposed	14449	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-11-10	Restricted Stock Unit	$	M	5885	Disposed		Common Shares (5885)	Direct

Footnotes

F1: Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on November 10, 2021.

F2: Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs. Pursuant to the terms of the applicable RSU grant agreement (the "Grant Agreement"), effective on the grant date of the RSUs, the Reporting Person adopted a 10b5-1 plan pursuant to which the Reporting Person elected to sell shares to cover tax withholding obligations and other applicable fees in accordance with the terms of the Grant Agreement.

F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.09 to $8.10, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F4: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.

F5: The RSUs were granted on November 10, 2021 and vest in three equal annual instalments beginning on November 10, 2022.